Abstract 503
Abstract 503 De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results. Nadia Harbeck, Oleg Gluz, Matthias Christgen, Sherko Kuemmel, Eva-Maria Grischke,…